Programs & products

Innate will receive 3m USD upfront plus up to 4.9m USD in conditional tranched investments from The Institute for Follicular Lymphoma Innovation (IFLI) Patients with R/R Follicular Lymphoma will be...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that abstracts related to lacutamab health-related quality of life and translational data from the...

IPH6501 is a first-in-class tetra-specific NK cell engager armed with a variant of IL-2, targeting CD20 and developed for B-NHL IPH6501 boosts NK cell proliferation and cytotoxicity, showing activity...

Jonathan Dickinson appointed Chief Executive Officer and Chairman of the Executive Board Encouraging initial FDA feedback received on lacutamab regulatory pathway Lacutamab health-related quality of...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that new preclinical data supporting the clinical development of its proprietary next generation...

IPH4502 is Innate’s novel and differentiated topoisomerase I inhibitor antibody drug conjugate (ADC) targeting Nectin-4 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “...

Positive results with lacutamab from TELLOMAK Phase 2 study in mycosis fungoides presented at ASCO 2024 NK-Cell engager SAR443579/IPH6101 1 first-in-human study advanced to Phase 2 and initiation of...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented interim results from the randomized NeoCOAST-2 (...

SAR443579/IPH6101, ANKET ® platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under...

In heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level. Lacutamab was well-tolerated...